Novartis Pharma AG Global Clinical Trials Innovation Summit
|
|
- Logan Walker
- 5 years ago
- Views:
Transcription
1 Novartis Pharma AG Global Clinical Trials Innovation Summit Cornelis Winnips MD, Global Program Medical Director Berlin, October 20, 2016
2 Novartis is one of the world s largest pharmaceutical companies... Sales By Region 2015 USD Billion Latin America Net Sales Net Income Asia/Africa/ Australasia 21% 9% 33% Europe People (FTEs) 118,700 37% US Clinical Trials Innovation Summit, Berlin , C.Winnips 2
3 Our mission and vision for sustainable growth Mission Discover new ways to improve and extend people s lives Using science-based innovation Delivering breakthrough treatments to as many people as possible Aim to provide shareholder return Vision Be a trusted leader in changing the practice of medicine Clinical Trials Innovation Summit, Berlin , C.Winnips 3
4 The Macro-Environment Opportunity and Change Business 4 Use Only
5 A golden age for medical science Accelerating Innovation +64% The US approved an average of 36 new drug molecules a year in , vs 22 in Clinical Trials Innovation Summit, Berlin , C.Winnips 5
6 Demographic trends are changing healthcare Growing Populations +1Bn by 2030 About 8.5 billion people are expected to inhabit the planet by the year 2030 Clinical Trials Innovation Summit, Berlin , C.Winnips 6
7 Demographic trends are changing healthcare Rapid Aging +500m over by About 1.4 billion people worldwide are projected to be 60 or older by the year 2030, fueling a rise in chronic illness Clinical Trials Innovation Summit, Berlin , C.Winnips 7
8 Putting healthcare systems under pressure Increasing Healthcare Demand 13T by 2025 If growth trends continue, global healthcare outlays could rise 70% by 2025 to USD 13 trillion Clinical Trials Innovation Summit, Berlin , C.Winnips 8
9 We need to Reimagine Medicine Use science- How we fight disease based innovation How we deliver treatments How we operate Clinical Trials Innovation Summit, Berlin , C.Winnips 9
10 ...and deliver better health outcomes for patients Outcome-based pricing Real-world evidence of effectiveness Data and analytics Digital health, beyond the pill Health system capacity building Clinical Trials Innovation Summit, Berlin , C.Winnips 10
11 Clinical Trial Environment Some Basics
12 Clinical Trials General Legal/Moral Framework Objectivity Good Clinical Practice! Public Interest Patient Interest Documentation 12 Clinical Trials Innovation Summit, Berlin , C.Winnips
13 Guiding Ideas and Principles Protection of humans is the utmost objective Guidelines are not laws but sensible help to navigate Economy: use first the most simple and quickest test system Results must be reproducable!!! Statistically significant is not identical to clinically relevant (medically meaningful) Be aware of the limitations preclinical and surrogate markers have for the relevance for humans and the target disease The dose plays the game (dosing interval; treatment duration; dose-response curve is linear, sigmoid, U-shaped, bellshaped) 13 Clinical Trials Innovation Summit, Berlin , C.Winnips
14 Drug Development Regulatory Dimensions 14 Clinical Trials Innovation Summit, Berlin , C.Winnips
15 15 Example of Today s Clinical and Commercial Challenges Increasing development hurdles?
16 Setting the scene prepare for access Product X, demonstrated efficacy in phase 3 trials in patients with moderate-to-severe disease compared with placebo or a current standard of care. Registration The global clinical program for registration included 6 placebo and active controlled studies in patients with moderate to severe disease. Label at submission was Second line : Product X is indicated for the treatment of moderate to severe disease in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies. Taken together, clinically highly relevant efficacy has been shown in patients with moderate to severe disease, including systemic treatment naïve patients as well as those previously exposed to systemic therapies including biologic therapies. Therefore, the EMEA agreed to broaden the initially proposed indication to: Product X is indicated for the treatment of moderate to severe disease in adults who are candidates for systemic therapy* Clinical Trials Innovation Summit, Berlin , C.Winnips
17 Example prepare for access in Germany Access The Patient Access team has highlighted the need for active controlled H2H RCT. The H2H studies are gateway to access for many countries, including some of the top 10 countries. Ideally the H2H are superiority studies vs the best comparator (efficacy/price). Access in Germany Demonstrate considerable therapeutic improvement In accordance with AMNOG (German Access Law), the German team needed to demonstrate considerable therapeutic improvement with Product X relative to an appropriate comparator, in order to receive a sustainable reimbursement price The German team identified Product Y as their primary choice of comparator vs. Product X. (existing H2H data). However, Product Z, a recent entrant in the indication, and which was considered for a next H2H by global, was also regarded as a possible comparator Add to existing trial data To add to the existing trial data for Product X versus Product Y, Global also initiated a phase 3b study, CLEAR, to assess the efficacy and safety of ProductX vs. ProductZ However, the G-BA did not consider ProductsY or Z to be appropriate comparators in the indication. This was because ProductY was not as effective as other available treatments and ProductZ had not been utilized enough in the healthcare system ProductXY as G-BA appropriate comparator The G-BA identified ProductXY or Product XX as appropriate comparators for product X Conducting a head-to-head trial of ProductX versus ProductXY or Product XX in the approved/ targeted patient population would generate high quality evidence that would meet G-BA comparator specifications, but would be expensive and time-consuming Clinical Trials Innovation Summit, Berlin , C.Winnips
18 Impact on Planning and Project Selection
19 Developing a quantitative Target Product Profile (TPP) Objective: The main objective is to support decision making where the aim is to develop a product to meet a medical and market need Approach: Define base case and upside quantitative targets for key efficacy and key safety outcomes in the TPP. Identify the relevant evidence to assess these targets Use probabilities to quantify the current evidence in relation to the TPP targets. Based on a results, align on a common interpretation and a set of recommendations Challenges: Requires a team discussion and alignment Potentially guided by a Biostatistician Ensure consistency! 19 Clinical Trials Innovation Summit, Berlin , C.Winnips
20 Defining a e Target Product Profile (TPP) Case study - Product X: Define TPP and the context of the program Drug Indication Standard of care Base case Including minimal acceptable thresholds Upside case Including target thresholds Product X Acute Heart Failure Usual care + Placebo Dyspnea (VAS): difference over 5 days in CFB 468 mm*hr (4mm on average) Dyspnea (Likert): prop of patient with moderate to marked improvement : RR 1.3 CV death and HF hosp at day 60: HR 0.85 Days alive out of hospital: 1 day improvement (60 days) All cause Mortality: RR 1 Clinical blood pressure: 15% decrease Dyspnea (VAS) difference over 5 days in CFB 585 mm*hr (5mm on average) Dyspnea (Likert): prop of patient with moderate to marked improvement : RR 1.4 CV death and HF hosp at day 60: HR 0.75 Days alive out of hospital: 2 days improvement (60 days) All cause Mortality: RR 0.7 Clinical blood pressure: 5% decrease Thresholds must be justified e.g. having a target threshold differentiates the New drug (this could be a non-inferiority margin in some cases e.g. antibiotics) 20 Clinical Trials Innovation Summit, Berlin , C.Winnips
21 Quantify the Clinical Data Product X: Collect the key phase III data Product X Standard of care Threshold stat: Difference to SoC TPP Base TPP Upside Dyspnea - VAS 2756mm 2308mm 447.7mm (120, 775.4) 468mm 585mm Efficacy Dyspnea - Likert CV death and HF hosp 27% 26% RR 1.04 (0.86,1.26) 13.1% 12.9% HR 1.02 (0.74, 1.41) Science Days alive out of hospital 48.3 (# days) (-0.77,1.97) 1 2 Safety AE of special interest All cause Mortality Clinical blood pressure decrease 7.2% 11.2% RR 0.63 ( 0.43, 0.93) 18.8% 12.5 % -6.3% (-10.5, -2.1) RR 1 RR % -5% Include the primary efficacy and AE of special interest for the program. 21 Clinical Trials Innovation Summit, Berlin , C.Winnips
22 What goes into the Holistic Assessment Framework to assess a Project? Science Grid Project Attributes Includes Time to launch, NPV, enpv and ROCE (return on capital employed) based on team input Science Therapeutic Differentiation Strength of Evidence ROI Time to launch NPV - enpv - ROCE Technical & Market Risk Clinical Endpoints Regulatory Risk Market Access Based on the information given in the Therapeutic Fact-Sheet 22 Clinical Trials Innovation Summit, Berlin , C.Winnips Based on short rationale given in the Data Capture Sheet under the section Technical & Market Risk
23 A Template for Clinical quantitative Assessment Process Define Target Product Profile and collate the key clinical data Efficacy Safety Quantify the TPP Summarize clinical data Efficacy Base Nov drug Upside Standard of care Diff Quantitative assessment of the data Probabilities quantifying the current evidence Visual representation Qualitative assessment of the data Mirrors the prioritization framework Generic set of descriptions to assess data Criteria Efficacy Safety Favorable (5) Neutral (3) Unfavorable (1) Judgement of the data Efficacy (5) (4) (3) (2) (1) Safety (5) (4) (3) (2) (1) Safety Clinical Trials Innovation Summit, Berlin , C.Winnips
24 Conclusions The Aligned Clinical Development Strategy 1. Is adapted to today s environment Increasing competition for limited healthcare resources Need for more rigorous generation of evidence Focus on Patient value & outcome 2. Meets medical and business goals Reflected in the Target Product Profile Comparison with «gold standard» where possible 3. Integrates evidence in standard templates Provides a consistent picture of all relevant data of a given project at a given time point Leads disciplined approach to decision making based on the evaluation of the current evidence related to clinical development and commercial objectives Uncertainty assessed by using two targets (base and upside cases) 24 Clinical Trials Innovation Summit, Berlin , C.Winnips
25 Novartis Pharma AG Thank you
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationModels for Computer-Aided Trial & Program Design
Models for Computer-Aided Trial & Program Design Terrence Blaschke, M.D. VP, Methodology and Science Pharsight Corporation & Professor of Medicine & Molecular Pharmacology Stanford University MODELS What
More informationBetter Portfolio Decisions through Predictive Analytics
Better Portfolio Decisions through Predictive Analytics Speakers Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics Karthik Subramanian, Competitive Intelligence & Clinical
More informationDisclosures. Shareholder: GlaxoSmithKline Spero Therapeutics. Consultant: Prokaryotics
Disclosures Shareholder: GlaxoSmithKline Spero Therapeutics Consultant: Prokaryotics The opinions expressed in this presentation are my own and are not necessarily shared by my industry colleagues Tomayko
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationDRUG DEVELOPMENT TARGET PRODUCT PROFILE
DRUG DEVELOPMENT TARGET PRODUCT PROFILE Template This template provides suggested considerations that may assist biopharmaceutical companies in their decisions as to whether to proceed with a drug development
More informationFirst Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors General Presentation, Fresenius SE & Co. KGaA, Investor Relations Copyright, August 2016
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationA LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements
More informationHealth Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona
Health Care Worldwide Crédit Suisse Global Credit Products Conference October 1, 2015 - Barcelona Safe Harbor Statement This presentation contains forward-looking statements that are subject to various
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationDEFINING BEST PRACTICE FOR ADVERSE EVENT REPORTING WITH INDUSTRY-SPONSORED CLINICAL TRIAL MANUSCRIPTS
11TH ANNUAL MEETING OF ISMPP DEFINING BEST PRACTICE FOR ADVERSE EVENT REPORTING WITH INDUSTRY-SPONSORED CLINICAL TRIAL MANUSCRIPTS April 28, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL
More informationRegulatory Market Update: What are the major changes and differences worldwide?
Regulatory Market Update: What are the major changes and differences worldwide? Marlene E. Haffner MD, MPH, CEO Haffner Associates Orphan Drug Summit 2015 Copenhagen, Denmark September 17, 2015 Orphan
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationThe Critical Path to TB Drug Regimens Initiative
The Critical Path to TB Drug Regimens Initiative Jan Gheuens, MD, PhD Global Health, Bill & Melinda Gates Foundation Addis Ababa, August 18th, 2010 The new tools that are needed to fight TB are on their
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationDisclosures. Learning Objectives. Modification of RSV Prophylaxis Recommendations in the 2009 Red Book Why Was it Done, and What Does it Mean for You?
Modification of RSV Prophylaxis Recommendations in the 2009 Red Book Why Was it Done, and What Does it Mean for You? David W. Kimberlin, M.D. Disclosures I have no actual or potential conflict of interest
More informationAvailability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for
This document is scheduled to be published in the Federal Register on 06/04/2013 and available online at http://federalregister.gov/a/2013-13083, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationIndustry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways
Industry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways Alan Poirier, Pfizer Inc. U.S. Regulatory Policy and Global Intelligence Worldwide Safety and Regulatory American
More informationValue Assessment: Building Payercentric value propositions to inform decision-making
Value Assessment: Building Payercentric value propositions to inform decision-making Aris Angelis and Panos Kanavos Medical Technology Research Group, LSE Health Advance-HTA dissemination workshop, Santiago,
More informationNIMH Updates and Research Priorities
NIMH Updates and Research Priorities ASCP Annual Meeting May 31, 2018 Shelli Avenevoli, Ph.D. Disclosure of Affiliations No conflicts of interest or disclosures 2 Agenda NIH and NIMH Updates NIMH Intervention
More informationCritical Path to TB Drug Regimens (CPTR)
Critical Path to TB Drug Regimens (CPTR) Why do we need a CPTR initiative? We finally have a pipeline of TB drug candidates Today, we test drugs same way we did 20 years ago Need better tests for drug
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationJMP JMP Pro JMP Genomics JMP Clinical JMP Add-Ins
JMP FAMILY OF PRODUCTS: SOFTWARE FOR LIFE SCIENTISTS JMP JMP Pro JMP Genomics JMP Clinical JMP Add-Ins CLINICAL TRIAL DATA REVIEWS Randomized clinical trial remains the gold standard for evaluating efficacy
More informationNEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY
SEPTEMBER 15, 2017 NEXT BIG WAVE IN PHARMACEUTICAL INDUSTRY Team Mavericks Smriti Mittal Pamela Mandal Harendra Prasad IIM Bangalore IIM Bangalore IIM Bangalore Smriti.mittal16@iimb.ernet.in pamela.mandal16@iimb.ernet.in
More informationProof of Concept Vs Proof of Value
Evidence Requirements Supporting Critical Decisions in Pharmacotherapeutics: Proof of Concept Vs Proof of Value RG Peterson MD, PhD, MPH Executive Director Drug Safety and Effectiveness Network Canadian
More informationThe Promise of Novel Clinical Trial Designs. Michael Parides, Ph.D. Mount Sinai School of Medicine
The Promise of Novel Clinical Trial Designs Michael Parides, Ph.D. Mount Sinai School of Medicine Productivity New Drug Approvals (NMEs) R&D Spending (billions) $12 $13 $13 $15 $49 $38 $39 $43 $30 $32
More informationEisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency
Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency This is not an official PMDA guidance or policy statement. No official support or endorsement by the PMDA is intended
More informationBiosimilars Clarified
Biosimilars Clarified 1 Learning Objectives Identify the key features of biological products and biosimilars Understand the biosimilar development pathway and clinical trials that assess biosimilarity
More informationEuropean perspectives: Real world outcome needs of payers, current and anticipated
European perspectives: Real world outcome needs of payers, current and anticipated ISCTM Washington DC, Feb 20, 2019 Emma Medin, MD, MSc Vice President, PAREXEL International Disclosure slide Emma Medin
More informationInterpreting Composite Endpoints in Cardiovascular in Clinical Trials
Interpreting Composite Endpoints in Cardiovascular in Clinical Trials Concepts and Controversies Paul W Armstrong MD ACC Rockies Banff Alberta March 13 2017 Disclosure Statement Paul W. Armstrong MD Research
More informationHarmonizing clinical trials for Biogenerics. Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK)
Harmonizing clinical trials for Biogenerics Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK) Senior Vice President & Global Head Global Medical Affairs (C.M.O) Dr. Reddy's Laboratories
More informationAMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA
News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone (805) 447-1000 Fax (805) 499-3507 www.amgen.com AMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION
More informationDefining the true market
Defining the true market Case study: How real-world data and outcomes improved a major pharmaceutical company s launch strategy Cardinal Health Specialty Solutions Competing in a crowded marketplace A
More informationMoving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment Matthias Egger Mike Chambers Univ. of Berne, Switzerland GSK, UK Slide 1 Increasingly complex external
More informationETHICAL, LEGAL AND SOCIAL ISSUES IN DRUG DEVELOPMENT AND PHARMACOGENOMICS: Report on a Qualitative Study of the Perspectives of Canadian Stakeholders
ETHICAL, LEGAL AND SOCIAL ISSUES IN DRUG DEVELOPMENT AND PHARMACOGENOMICS: Report on a Qualitative Study of the Perspectives of Canadian Stakeholders SHANNON GIBSON University of Toronto Faculty of Law
More informationUS FDA Expedited Programs and Expanded Access
US FDA Expedited Programs and Expanded Access Ke Liu, MD, PhD Chief, Oncology Branch Division of Clinical Evaluation, Pharmacology and Toxicology Office of Tissues and Advanced Therapies Center for Biologics
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationRegulatory hurdles and opportunities
Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public
More informationAchieving Mayo s s Value Equation: The Role of Systems and Procedures
Achieving Mayo s s Value Equation: The Role of Systems and Procedures AIMC Health Care Workshop April 28, 2010 Sharon Gabrielson, BS, MA Section Head, Systems and Procedures Mayo Clinic, Rochester, MN
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationFrom discussion to implementation: How to negotiate and implement a risk-sharing agreement
July 2017 From discussion to implementation: How to negotiate and implement a risk-sharing agreement At the table with payers and manufacturers Background The groundswell of interest in value-based drug
More informationNon-Inferiority Trials: What are they and why are they so difficult?
Non-Inferiority Trials: What are they and why are they so difficult? David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research Saint-Luke Luke s s Mid America Heart Institute Professor of Medicine
More informationHealth Care Business Group
Health Care Business Group Joaquin Delgado, Executive Vice President December 17, 2013 2013 3M. All Rights Reserved. 2 3M CONFIDENTIAL 2013 3M. All Rights Reserved. Saving and improving lives around the
More informationEnterprise Performance Management in the Pharmaceutical Industry. kpmg.co.uk
Enterprise Performance Management in the Pharmaceutical Industry kpmg.co.uk Are your performance management processes, metrics and tools prepared for tomorrow s strategic challenges in pharmaceuticals?
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationMaximize the Collection of Real- World Data in Expanded Access Programs
Maximize the Collection of Real- World Data in Expanded Access Programs Jose Ricardo Perez, MD. Executive Medical Director Novartis Oncology East Hanover, NJ Disclaimer: The opinions expressed in this
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationCompany Profile. German-Taiwan Biotech Seminar 6 November 2017
Company Profile German-Taiwan Biotech Seminar 6 November 2017 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical
More informationChallenges in receptor occupancy determination assays by flow cytometry in drug development
Challenges in receptor occupancy determination assays by flow cytometry in drug development DATE 17 November 2016 PRESENTED BY Martine Broekema, Ph.D. Associated Director of Bioanalytical Sciences Large
More informationUPS Healthcare Supply Chain Vital Signs
UPS Study Executive September 2017 START 2017 UPS Survey 2017 United Parcel Service of America, Inc. 1 An industry growing more complex: managing competition, compliance and costs Pharmacies are grappling
More informationThe Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
More informationIDSA is pleased to offer the following comments on specific priority areas identified by FDA:
October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development
More informationJ.P. Morgan Healthcare Conference. Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO
J.P. Morgan Healthcare Conference Jeffrey Leiden, M.D., Ph.D., Chairman, President and CEO January 8, 2018 Safe Harbor Statement & Non-GAAP Financial Measures This presentation contains forward-looking
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationPortfolio Management at Bayer Pharmaceuticals. Matthias Gottwald Head R&D Policy and Networks Bayer HealthCare
Portfolio Management at Bayer Pharmaceuticals Matthias Gottwald Head R&D Policy and Networks Bayer HealthCare September 24, 2015 Agenda Project Management Portfolio Management Page 2 CEMDC 2015 Project
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationReflection paper on the use of extrapolation in the development of medicines for paediatrics
1 2 3 9 October 2017 EMA/199678/2016 4 5 6 Reflection paper on the use of extrapolation in the development of medicines for paediatrics Draft Draft agreed by Biostatistics Working Party September 2017
More informationFDA from a Former FDAer: Secrets and insights into regulatory review and drug development
FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA
More informationCorporate Presentation February 2016
Corporate Presentation February 2016 Issuer Free Writing Prospectus dated February 25, 2016 Filed Pursuant to Rule 433 Registration Statement No. 333 209454 Forward Looking Statements This presentation
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationFOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY
WHITE PAPER FOCUS REIMBURSEMENT STRATEGY TO DEMONSTRATE FULL VALUE STORY By Nicole May, Research Analyst at Cutting Edge Information OVERVIEW National and private payers, especially in the US and EU, are
More informationComparative Oncology Program
The Problem: Non-Integrated Cancer Drug Development A Solution: Integration of Informative Non-Clinical Models of Cancer With Clinical Drug Development Efforts Companion Animal Malignancies as Comparative
More informationICON plc. 10th Jan Ciaran Murray CEO Steve Cutler CEO Designate. JP Morgan 35TH Annual Healthcare
ICON plc Ciaran Murray CEO Steve Cutler CEO Designate JP Morgan 35TH Annual Healthcare 10th Jan 2017 Forward Looking Statement Certain statements will be forward looking statements. Actual results may
More informationNew Drug Application (NDA) Webinar December 6, 2016
New Drug Application (NDA) Webinar December 6, 2016 Introduction Presenter: Jill Jarecki Chief Scientific Officer, Cure SMA New Drug Application Process NDA Not yet an approved therapy: ~90% chance of
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationBiosimilar Medicines: Opportunities for Sustainable Healthcare. Opening Address Greg Perry Director General EGA London 3-4 May 2007
Biosimilar Medicines: Opportunities for Sustainable Healthcare Opening Address Greg Perry Director General EGA London 3-4 May 2007 Building on The Generic Medicines Legacy 1. Generic medicines account
More informationIdentifying Critical Factors Pre-launch
Identifying Critical Factors Pre-launch Incorporate pricing and market access into product planning Eric M. Bachman, Director Boston office One Canal Park Cambridge, MA 02141, USA Tel. +1 617 231 4592
More informationRegulatory Statistical Perspectives on Safety Issues in Drug Development
Regulatory Statistical Perspectives on Safety Issues in Drug Development C. George Rochester, Ph.D. Lead Statistician for Drug Safety Evaluation Food & Drug Administration, Rockville, MD, USA RochesterG@cder.fda.gov
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationThe importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
More informationEthical approaches to Innovation in Global Health
Georg Marckmann Institute of Ethics, History and Theory of Medicine Ethical approaches to Innovation in Global Health World Health Summit Satellite Event Innovation in Health: The contribution of biologic
More informationThe New Role of Medical Affairs in Defining and Driving Product Success
The New Role of Medical Affairs in Defining and Driving Product Success Suma Ramadas, PhD, and Susan Suponcic, PhD Syneos Health Consulting 2018 Syneos Health. All rights reserved. The Organizational Role
More informationRe: National Coverage Analysis (NCA) Tracking Sheet for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)
June 15, 2018 Katherine B. Szarama, PhD Lead Analyst Coverage and Analysis Group Centers for Medicare & Medicaid Services Department of Health and Human Services 7500 Security Blvd. Baltimore, MD 21244
More information3 Phases of Investigation
Part I: The scientific setting - December 30, 2009, 1 3 Phases of Investigation As discussed in Chapter 1, science is adversarial; scientists should consider all possible hypotheses, and only eliminate
More informationFORWARD THINKING HEALTHCARE
AT A 2018 GLANCE 02 FORWARD THINKING HEALTHCARE Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 270,000 employees
More informationPluristem Issues Letter to Shareholders
Pluristem Issues Letter to Shareholders HAIFA, Israel, January 30, 2014 -- Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today issued a
More informationFirst Quarter 2017 Earnings Teleconference April 27, 2017
First Quarter 2017 Earnings Teleconference April 27, 2017 1Q17 Earnings Call Agenda Introduction CEO Opening Remarks Financial Update Commercial Highlights R&D Highlights CEO Closing Remarks Q&A Elena
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More informationProgram Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
More informationStatement on Regulatory Systems to Improve Pharmaceutical Safety
International Society for Pharmacoepidemiology (ISPE) Statement on Regulatory Systems to Improve Pharmaceutical Safety INTRODUCTION The public, some researchers, individual regulators and policymakers
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationThe rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation
The rheumatoid arthritis drug development model: a case study in Bayesian clinical trial simulation Richard Nixon, Modeling and Simulation, Novartis PSI journal club, 2010 March 24 1 Bayesian clinical
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationField trial with veterinary vaccine
١ Field trial with veterinary vaccine Saeedeh Forghani,, M.D. Clinical Trial and Ethics Department Human Health Management Deputy of Quality Assurance 89/4/2 ٢ ٣ Introduction: The efficacy and safety shall
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationAustralian Medical Research and Innovation Priorities Determination 2018
Australian Medical Research and Innovation Priorities 2018 2020 Determination 2018 I, Ian Frazer, Chair of the Australian Medical Research Advisory Board, make the following instrument on behalf of the
More informationAdvancing Mitochondrial Medicine. Günther Metz, SVP Business Development
Advancing Mitochondrial Medicine Günther Metz, SVP Business Development Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to
More informationDose Exposure Response Relationships: the Basis of Effective Dose-Regimen Selection
Dose Exposure Response Relationships: the Basis of Effective Dose-Regimen Selection Model-Based Solutions to a Calibration Problem Michael Looby, Novartis Peter Milligan, Pfizer Dose Regimen Selection:
More informationehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014
ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 Health care is in the middle of a perfect storm Changing demographics Unmet needs
More informationSetting the Scene - Industry. Regulatory Science. Merete Schmiegelow Senior Director, Regulatory Policy
CORS-Industry-241116 1 Regulatory Science Setting the Scene - Industry Merete Schmiegelow Senior Director, Regulatory Policy Honorary Industrial Ambassador in Regulatory Science at the University of Copenhagen
More informationModels of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics
Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Safety Evaluation is Not Completed at Approval Phase 3 programs evaluate efficacy and general safety/tolerability
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationPharmaco-Epidemiological Studies. A French experience
Pharmaco-Epidemiological Studies A French experience CVZ, Diemen, December 1 st, 2006 Hubert MECHIN, MD CEO MAPI-NAXIS Lyon, France Vocabulary Pharmaco epidemiological studies Observational studies Post-authorization
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationINVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!
INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationMy Experiences as an FDA Statistician
My Experiences as an FDA Statistician Yeh-Fong Chen, Ph.D. FDA/CDER/OB/DB3 CBA 2016-2017 Workshop series-3 Dec. 18, 2016 Disclaimer This presentation reflects the views of the author and should not be
More information